- –
Jose A. Caminero, University General Hospital of Gran Canaria Dr Negrin, Las Palmas, Spain and MDR-TB Unit Coordinator, The UNION, Paris, France – (Clinical practice, representative from gGLC)
- –
Richard E. Chaisson, Johns Hopkins University School of Medicine, USA (trialist, clinician, HIV/TB specialist)
- –
Gavin Churchyard, Chief Executive Officer, Aurum Institute for Health Research, Johannesburg, South Africa – (STAG-TB member, Clinical practice, TB, TB/HIV, research, drug and vaccine development)
- –
Anna Marie Celina Garfin, Department of Health – National Center for Disease Prevention and Control, Philippines – (Programme management, end-user)
- –
Giovanni Battista Migliori, Director of WHO Collaborating Centre for TB and Lung Diseases Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy – (STAG-TB member, pulmonologist/MDR-/XDR-TB expert and TB technical adviser)
- –
Rohit Sarin, Director, National Institute of TB & Respiratory Diseases (NITRD), Sri Aurobindo Marg, New Delhi, India – (Clinical consultant in TB and Respiratory Diseases, member of rGLC SEAR, end-user).
- –
Maarten van Cleeff, KNCV Tuberculosis Foundation, The Hague, The Netherlands – (STAG-TB member, TB, TB/HIV, poverty and ethics, diagnosis, health system strengthening, operational research, monitoring and programme evaluation).
- –
Andrew Vernon, US Centers for Disease Control and Prevention (CDC), USA (trialist, clinician, surveillance)
